Additionally, Zfra4-10 blocks NF-κB-mediated inflammation and accelerates degradation of proteins in the AD pathologies, as well as induction of the activation of HYAL-2+ CD3− CD19− lymphocytes to kill cancer in vivo [50,51,52,53]. Here, NFKB1 is linked to cancer.